LN
Therapeutic Areas
Altay Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DX5057 | Facioscapulohumeral Muscular Dystrophy (FSHD) | Preclinical |
| STAT3 Inhibitor | Inflammatory Diseases & Oncology | Lead Optimization |
| Undisclosed Oncology Program | Sarcomas and Prostate Cancer | Lead Optimization |
Leadership Team at Altay Therapeutics
MG
Mike Grey
Executive Chair, Board of Directors
EB
Eric Bjerkholt
Board of Directors
EC
Eva Chin, Ph.D.
Board of Directors
AO
Ali Ozes, Ph.D.
Founder & CEO, Board of Directors
ON
Osman N. Ozes, Ph.D.
Founder
AD
Alejandro Dorenbaum, M.D.
Chief Medical Officer
JB
Jason Brittain, Ph.D.
Drug Product
KJ
Klaus Jensen, Ph.D.
DMPK
LL
Lee Latimer, Ph.D.
MedChem
NL
Noopur Liffick, MPH
Advisor